Search
Capricor Therapeutics Inc
CAPRAdd to Watchlist
3.850USD
-0.340-8.11%
Close 07-31 16:00（ET）Quotes delayed by 15 min
222.96MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-31The current earnings forecast score of Capricor Therapeutics Inc is 8.22, ranking 154 out of 385 in the Biotechnology & Medical Research industry. The average price target is 47.50, with a high of 62.00 and a low of 20.00.
Analyst Rating
Based on
10
analysts
Hold
Current Rating
4.900
Target Price
+27.27%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Capricor Therapeutics Inc
CAPR
10
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
Kymera Therapeutics Inc
KYMR
24
Insmed Inc
INSM
23
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Capricor Therapeutics Inc's price target?
Analysts forecast that Capricor Therapeutics Inc's price target is USD 47.50, with the highest forecast at USD 62.00 and the lowest forecast at USD 20.00.
How have Capricor Therapeutics IncCAPR's recent earnings per share performed?
The market expectation was USD -0.59, while Capricor Therapeutics IncCAPR's earnings per share (EPS) for the previous quarter was USD -0.62. EPS for the next quarter is expected at USD -0.59.
What is the analyst rating for Capricor Therapeutics Inc?
Based on the ratings of Capricor Therapeutics Inc's stock from 10 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.